QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:ACON

Aclarion - ACON Stock Forecast, Price & News

$0.82
+0.01 (+1.23%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.75
▼
$0.83
50-Day Range
$0.55
▼
$0.83
52-Week Range
$0.38
▼
$4.05
Volume
17,161 shs
Average Volume
37,478 shs
Market Capitalization
$6.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Aclarion MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
264.0% Upside
$3.00 Price Target
Short Interest
Healthy
1.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$12,043 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

See Top Rated MarketRank™ Stocks Here

ACON stock logo

About Aclarion (NASDAQ:ACON) Stock

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Receive ACON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter.

ACON Stock News Headlines

March 17, 2023 | americanbankingnews.com
Analyzing Aclarion (NASDAQ:ACON) & Progenity (NASDAQ:PROG)
March 7, 2023 | finance.yahoo.com
Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor
March 23, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
February 16, 2023 | finance.yahoo.com
Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023
February 15, 2023 | finance.yahoo.com
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium
February 5, 2023 | finance.yahoo.com
Insiders who bought stock earlier this year lose -US$213k as Aclarion, Inc. (NASDAQ:ACON) drops to US$4.7m
January 31, 2023 | finance.yahoo.com
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor
January 17, 2023 | finanznachrichten.de
The Investor Summit: Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event
March 23, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
January 17, 2023 | finance.yahoo.com
Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event
January 17, 2023 | finance.yahoo.com
Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor
December 22, 2022 | finance.yahoo.com
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
December 21, 2022 | finance.yahoo.com
Aclarion’s Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD
December 19, 2022 | finance.yahoo.com
Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor
December 1, 2022 | finance.yahoo.com
Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker
November 30, 2022 | reuters.com
ACON.OQ - Aclarion Inc | Stock Price & Latest News | Reuters
November 16, 2022 | finance.yahoo.com
Aclarion Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
October 25, 2022 | finance.yahoo.com
Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV
October 24, 2022 | finance.yahoo.com
Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor
October 12, 2022 | finance.yahoo.com
Aclarion To Present at The LD Micro Main Event XV
October 10, 2022 | finanznachrichten.de
Aclarion Inc.: Aclarion Announces Participation at the NASS 37th Annual Meeting
October 10, 2022 | finance.yahoo.com
Aclarion Announces Participation at the NASS 37th Annual Meeting
October 5, 2022 | finanznachrichten.de
Aclarion Inc.: John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor
October 3, 2022 | finance.yahoo.com
John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor
September 20, 2022 | finanznachrichten.de
Aclarion Inc.: Nociscan Selected for Inclusion in Pivotal National Institutes of Health Study for Low Back Pain
September 19, 2022 | finance.yahoo.com
Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain
August 22, 2022 | msn.com
Peering Into Aclarion's Recent Short Interest
See More Headlines
Receive ACON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter.

ACON Company Calendar

Today
3/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACON
CUSIP
N/A
CIK
1635077
Web
www.aclarion.com
Phone
833-275-2266
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+264.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,610,000.00
Net Margins
-12,583.55%
Pretax Margin
-12,583.55%
Return on Equity
N/A
Return on Assets
-206.46%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.40
Quick Ratio
1.40

Sales & Book Value

Annual Sales
$60,000.00
Price / Sales
107.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.23 per share
Price / Book
3.58

Miscellaneous

Outstanding Shares
7,860,000
Free Float
6,124,000
Market Cap
$6.48 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Jeffrey John Thramann M.D. (Age 58)
    Exec. Chairman
    Comp: $300k
  • Mr. Brent Ness (Age 56)
    CEO, Pres & Director
    Comp: $339.6k
  • Mr. John Lorbiecki (Age 59)
    Chief Financial Officer
    Comp: $225k
  • Mr. Ryan Bond (Age 48)
    Chief Strategy Officer
    Comp: $202.6k

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













ACON Stock - Frequently Asked Questions

Should I buy or sell Aclarion stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclarion in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACON shares.
View ACON analyst ratings or view top-rated stocks.

What is Aclarion's stock price forecast for 2023?

1 brokers have issued 12-month price objectives for Aclarion's shares. Their ACON share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 264.0% from the stock's current price.
View analysts price targets for ACON or view top-rated stocks among Wall Street analysts.

How have ACON shares performed in 2023?

Aclarion's stock was trading at $0.58 at the beginning of the year. Since then, ACON stock has increased by 42.1% and is now trading at $0.8241.
View the best growth stocks for 2023 here.

When did Aclarion IPO?

(ACON) raised $12 million in an IPO on Friday, April 22nd 2022. The company issued 2,165,000 shares at a price of $4.50-$6.50 per share.

What is Aclarion's stock symbol?

Aclarion trades on the NASDAQ under the ticker symbol "ACON."

How do I buy shares of Aclarion?

Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclarion's stock price today?

One share of ACON stock can currently be purchased for approximately $0.82.

How much money does Aclarion make?

Aclarion (NASDAQ:ACON) has a market capitalization of $6.48 million and generates $60,000.00 in revenue each year.

How can I contact Aclarion?

Aclarion's mailing address is 951 MARINERS ISLAND BLVD STE 300, SAN MATEO CA, 94404. The official website for the company is www.aclarion.com. The company can be reached via phone at 833-275-2266.

This page (NASDAQ:ACON) was last updated on 3/23/2023 by MarketBeat.com Staff